Company Analysis

Redhill Biopharma Ltd. (RDHL)

Nasdaq: RDHL · Pharmaceutical Preparations · Tel Aviv, IL · filing with the SEC since 2012
Grade3.9
◀ Past 5.1● Present 3.5▶ Future 3.6
2 est.

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

42 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Redhill Biopharma Ltd.’s names, not what it holds today.

Patents granted
42
41 utility, 1 design, 1976 to Dec 31, 2025
Granted in 2025
2
Against 4 in 2024 and 3 in 2023
Applications published
48
1 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals19
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
RedHill Biopharma Ltd. its own name
IL, as the owner printed on each patent
42 granted
8 published
RedHill Biopharma Ltd. its own name
named as the applicant on its applications, in IL
0 granted
40 published
Newest grantseach row opens the USPTO’s own copy
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 23, 20252025/0325577THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATIONPharmaceuticalsRedHill Biopharma Ltd.
Oct 24, 20242024/0350461SERINE PROTEASE INHIBITOR FOR TREATING CORONAVIRUS INFECTIONPharmaceuticalsRedHill Biopharma Ltd. · patent 12,502,381 granted from it
Oct 3, 20242024/0325313PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORIPharmaceuticalsRedHill Biopharma Ltd.
Apr 4, 20242024/0108643THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATIONPharmaceuticalsRedHill Biopharma Ltd. · patent 12,370,206 granted from it
Mar 28, 20242024/0100034METHOD FOR ERADICATING HELICOBACTER PYLORI INFECTION IN PATIENTS REGARDLESS OF BODY MASS INDEXPharmaceuticalsRedHill Biopharma Ltd.
Jan 5, 20232023/0000845BIOMARKERS OF CORONAVIRUS PNEUMONIAPharmaceuticalsRedHill Biopharma Ltd. · patent 12,115,150 granted from it
Jun 16, 20222022/0184053SPHINGOSINE KINASE 2 INHIBITOR FOR TREATING CORONAVIRUS INFECTION IN MODERATELY SEVERE PATIENTS WITH PNEUMONIAPharmaceuticalsRedHill Biopharma Ltd. · patent 11,471,448 granted from it
Mar 3, 20222022/0062188ALL-IN-ONE FIXED-DOSE COMBINATION FOR TREATING HELICOBACTER PYLORI INFECTIONPharmaceuticalsRedHill Biopharma Ltd. · patent 11,931,463 granted from it
Feb 3, 20222022/0031682SPHINGOSINE KINASE 2 INHIBITOR FOR TREATING CORONAVIRUS INFECTIONPharmaceuticalsRedHill Biopharma Ltd. · patent 11,364,227 granted from it
Dec 30, 20212021/0401865TRIPLE ANTIBIOTIC FIXED-DOSE COMBINATION PRODUCTS, DOSING REGIMEN, METHODS, AND KITS FOR TREATING PULMONARY NON-TUBERCULOSIS MYCOBACTERIAL INFECTIONSPharmaceuticalsRedHill Biopharma Ltd. · patent 11,590,154 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 5.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton RDHL · research, not advice